Dr. Solin Discusses the DCIS Score Recurrence Test

Lawrence J. Solin, MD
Published: Wednesday, Dec 07, 2011

Lawrence J. Solin, MD, chair, Department of Radiation Oncology, Einstein Medical Center, discusses a new multigene assay designed to predict recurrence risk in patients with ductal carcinoma in situ (DCIS). The new test labeled the DCIS Score uses the Oncotype DX breast cancer assay and an optimized gene expression algorithm to sort patients into the three groups low-, intermediate-, or high-risk.

The treatment decision for patients with DCIS is currently based upon clinical and pathological parameters such as the size and grade of the tumor. From this initial inspection many patients are able to receive a lumpectomy, or a lumpectomy in addition to radiation.

Predicting the individual risk will provide a more tailored treatment for each patient and will reduce the amount of unneeded radiation received. Read more about the study >>> New Test Predicts Recurrence Risk in Patients With Ductal Carcinoma in Situ


>>>Return to the main conference coverage page.
Lawrence J. Solin, MD, chair, Department of Radiation Oncology, Einstein Medical Center, discusses a new multigene assay designed to predict recurrence risk in patients with ductal carcinoma in situ (DCIS). The new test labeled the DCIS Score uses the Oncotype DX breast cancer assay and an optimized gene expression algorithm to sort patients into the three groups low-, intermediate-, or high-risk.

The treatment decision for patients with DCIS is currently based upon clinical and pathological parameters such as the size and grade of the tumor. From this initial inspection many patients are able to receive a lumpectomy, or a lumpectomy in addition to radiation.

Predicting the individual risk will provide a more tailored treatment for each patient and will reduce the amount of unneeded radiation received. Read more about the study >>> New Test Predicts Recurrence Risk in Patients With Ductal Carcinoma in Situ


>>>Return to the main conference coverage page.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x